Select Language

ICOS

ICOS Overview

English Name	Inducible T-cell costimulator	Approved Drugs	0
Drugs in Clinical Trials	7	Target Synonym	Activation-inducible lymphocyte immunomediatory molecule，Inducible T-cell costimulator，ICOS，CD278，AILIM，Inducible T Cell Costimulator，Inducible T-Cell Co-Stimulator，Inducible Costimulator，CD278 Antigen，CVID1，Inducible T-Cell Co-Stimulator Protein
Highest Development Stage	Phase 2 Clinical

English Name	Inducible T-cell costimulator
Target Synonym	Activation-inducible lymphocyte immunomediatory molecule，Inducible T-cell costimulator，ICOS，CD278，AILIM，Inducible T Cell Costimulator，Inducible T-Cell Co-Stimulator，Inducible Costimulator，CD278 Antigen，CVID1，Inducible T-Cell Co-Stimulator Protein
Approved Drugs	0
Drugs in Clinical Trials	7
Highest Development Stage	Phase 2 Clinical

ICOS Product List

Product Category
Protein (6)
Product Status
Launched (6)
Species
Human (3)Mouse (2)Rat (1)
Tag
His Tag & Avi Tag (1)Fc Tag (2)His Tag (3)
Conjugate
Biotin-labeled (1)Unconjugated (5)

Cat. No.	Species	Host	Product Description
HOT ICS-H5258	Human	HEK293	Human ICOS / CD278 Protein, Fc Tag
HOT ICS-H52Ha	Human	HEK293	Human ICOS / CD278 (C136S, C137S) Protein, His Tag, active dimer (MALS verified)
HOT ICS-H82E5	Human	HEK293	Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning)
HOT ICS-M52H8	Mouse	HEK293	Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag
ICS-M5259	Mouse	HEK293	Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag
ICS-R52H9	Rat	HEK293	Rat ICOS / CD278 (C137S, C138S) Protein, His Tag

Total: 6

ICOS Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS Synonyms

ICOS,CD278,AILIM,Inducible T-cell costimulator

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Vopratelimab	JTX-2011	Phase 2 Clinical	Jounce Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Neoplasms	Details
Feladilimab	GSK-609; GSK-3359609	Phase 2 Clinical	Glaxosmithkline Plc	Head and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
Acazicolcept	ALPN-101	Phase 2 Clinical	Alpine Immune Sciences Inc	Autoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders	Details
MEDI-570		Phase 1 Clinical	Japan Tobacco (Hong Kong) Ltd	Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides	Details
Izuralimab	XmAb-23104; XmAb-104	Phase 1 Clinical	Xencor Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
Anti-ICOS (Bristol Myers Squibb)	BMS-986226	Phase 1 Clinical	Bristol-Myers Squibb Company	Neoplasms	Details
anti-ICOS mAb (Bristol-Myers Squibb)		Phase 1 Clinical	Bristol-Myers Squibb Company	Neoplasms; Solid tumours	Details